$SRRK News

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Scholar Rock Q1 Earnings Call Highlights

Scholar Rock (SRRK) Q1 2026 Earnings Transcript

Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55

HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65

A Look At Scholar Rock (SRRK) Valuation After Strong Multi Year Shareholder Returns

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

Scholar Rock (SRRK) Q1 Loss Narrows In Line Awaits PDUFA Decision

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Scholar Rock (SRRK) Deepens SMA Manufacturing Footprint: Strategic Resilience Move or Regulatory Risk Signal?

Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $58

Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept.

Scholar Rock Holding Corporation (SRRK) Discusses BLA Resubmission for Apitegromab in Spinal Muscular Atrophy and Regulatory Progress Transcript

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Holding shares are trading higher after the company announced resubmission of its Biologics License Application for apitegromab for the treatment of spinal muscular atrophy to the FDA, with an expected PDUFA date in late September 2026.